Christopher Brittain

Christopher Brittain, MBBS, BSc, MBA, MRCOphth is Genentech’s VP and Global Head of Ophthalmology Product Development. Previously, Christopher led the development team for the Port Delivery System with ranibizumab (PDS), and prior to that led the clinical team working on lampalizumab, which was investigated for geographic atrophy secondary to age-related macular degeneration (AMD), during which time he moved from Roche in Basel, Switzerland to Genentech, San Francisco. Prior to joining Roche, Christopher served as Senior Medical Advisor at Novartis UK, and subsequently as the Head of Medical Affairs and Scientific Operations for Alcon UK. In addition, Christopher has served as Senior Medical Officer in the Clinical Devices Directorate of the Medicines and Healthcare Products Regulatory Agency (MHRA), an agency of the UK Department of Health, working on the safe and effective use of medicines and medical devices. A member of the UK Royal College of Ophthalmologists, Christopher received his Bachelor of Medicine and Bachelor of Surgery from St. George’s, University of London and his Master of Business Administration degree from the Imperial College of London.